Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 64

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 64
---
 parties to conduct our clinical trials swiftly and effectively;                                                                    |
| ● | launch of commercial sales of our drug candidates, if and when approved;                                                                             |
| ● | obtaining and maintaining patents, trade secrets and other IP protection and regulatory exclusivity, as well as protecting our rights in our own IP; |
| ● | ensuring that we do not infringe, misappropriate or otherwise violate patents, trade secrets or other IP rights of other parties;                    |
| ● | obtaining acceptance of our drug candidates by doctors and patients;                                                                                 |

| ● | obtaining reimbursement from third-party payors for our drug candidates, if and when approved;                           |
| ● | our ability to compete with other drug candidates and drugs; and                                                         |
| ● | maintenance of an acceptable safety profile for our drug candidates following regulatory approval, if and when received. |

We may not achieve regulatory
approval and commercialization in a timely manner or at all. Significant delays in obtaining approval for and/or to successfully commercialize
our drug candidates would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue
our operations.

Risks Related to Our IP

A significant portion of our IP portfolio currently includes pending patent applications that have not yet been issued as granted patents and if the pending patent applications covering our product candidates fail to be issued, our business will be adversely affected. If we or our licensors are unable to obtain and maintain patent protection for our technology and drugs, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be adversely affected.

Our success depends largely
on our ability to obtain and maintain patent protection and other forms of IP rights for the composition of matter, method of use
and/or method of manufacture for each of our drug candidates. Failure to obtain, maintain protection, enforce or extend adequate patent
and other IP rights could materially adversely affect our ability to develop and market one or more of our drug candidates. We also rely
on trade secrets and know-how to develop and maintain our proprietary and IP position for each of our drug candidates. Any failure to
protect our trade secrets and know-how with respect to any specific drug and diagnostics technology candidate could adversely affect the
market potential of that potential product.

As of the date of this prospectus,
the Company has, through its licenses, obtained rights to patents and patent applications covering some or all its drug and diagnostics
technology candidates that have been filed in major jurisdictions such as the United States